Search

Your search keyword '"Ortega‐Paz, Luis"' showing total 467 results
Start Over Author "Ortega‐Paz, Luis"
467 results on '"Ortega‐Paz, Luis"'

101. Safety and efficacy of different prophylactic anticoagulation dosing regimens in critically and non-critically ill patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials

Author

Ortega-Paz, Luis, primary, Galli, Mattia, additional, Capodanno, Davide, additional, Franchi, Francesco, additional, Rollini, Fabiana, additional, Bikdeli, Behnood, additional, Mehran, Roxana, additional, Montalescot, Gilles, additional, Gibson, C Michael, additional, Lopes, Renato D, additional, Andreotti, Felicita, additional, and Angiolillo, Dominick J, additional

Published
2021
Full Text
View/download PDF

103. COVID‐19 Associated Thrombosis and Coagulopathy: Review of the Pathophysiology and Implications for Antithrombotic Management

Author

Ortega‐Paz, Luis, Capodanno, Davide, Montalescot, Gilles, Angiolillo, Dominick, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona (UB), University of Catania [Italy], Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), and University of Florida [Gainesville] (UF)

Subjects
Pharmacology, myocardial infarction, endothelium, anticoagulant therapy, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, SARS-CoV-2, platelets, Anticoagulants, Thrombosis COVID-19, Coronary Artery Disease, thrombosis, antiplatelet therapy
Abstract

International audience; Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) which has posed a significant threat to global health. Although the infection is frequently asymptomatic or associated with mild symptoms, in a small proportion of patients it can produce an intense inflammatory and prothrombotic state that can lead to acute respiratory distress syndrome, multiple organ failure, and death. Angiotensinconverting enzyme 2 (ACE2), highly expressed in the respiratory system, has been identified as a functional receptor for SARS-CoV-2. Notably, ACE2 is also expressed in the cardiovascular system and there are multiple cardiovascular implications of COVID-19. Cardiovascular risk factors and cardiovascular disease have been associated with severe manifestations and poor prognosis in patients with COVID-19. Importantly, patients with COVID-19 may have thrombotic and coagulation abnormalities promoting a hypercoagulable state, resulting in an increased rate of thrombotic and thromboembolic events. This review will describe the pathophysiology of the cardiovascular involvement following infection by SARS-CoV-2, with a focus on thrombotic and thromboembolic manifestations and implications for antithrombotic management.

Published
2021
Full Text
View/download PDF

104. Effect of implantation technique on outcomes in patients receiving bioresorbable scaffolds in various clinical scenarios

Author

Ortega-Paz, Luis, primary, Brugaletta, and, Salvatore, additional, Capodanno, Davide, additional, Gómez-Hospital, Joan A., additional, Íñiguez, Andrés, additional, Gori, Tommaso, additional, Urbano, Cristóbal, additional, Nef, Holger, additional, Trillo, Ramiro, additional, Latib, Azeem, additional, Benedicto, Amparo, additional, Caramanno, Giuseppe, additional, de Prado, Armando Pérez, additional, Di Mario, Carlo, additional, Naber, Christoph, additional, Salinas, Pablo, additional, Sanchis, Juan, additional, Mehilli, Julinda, additional, Piñón, Pablo, additional, Martins, Dinis, additional, Avanzas, Pablo, additional, López-Mínguez, José R., additional, Martins, Cristina, additional, Santos, Ricardo, additional, Torres, Alfonso, additional, Lozano, Íñigo, additional, Moreno, Raúl, additional, Sabaté, Manel, additional, and Hernández, Felipe, additional

Published
2021
Full Text
View/download PDF

105. Efecto de la técnica de implantación en los resultados en pacientes tratados con armazón bioabsorbible en diferentes escenarios clínicos

Author

Ortega-Paz, Luis, primary, Brugaletta, Salvatore, additional, Capodanno, Davide, additional, Gómez-Hospital, Joan A., additional, Íñiguez, Andrés, additional, Gori, Tommaso, additional, Urbano, Cristóbal, additional, Nef, Holger, additional, Trillo, Ramiro, additional, Latib, Azeem, additional, Benedicto, Amparo, additional, Caramanno, Giuseppe, additional, de Prado, Armando Pérez, additional, Di Mario, Carlo, additional, Naber, Christoph, additional, Salinas, Pablo, additional, Sanchis, Juan, additional, Mehilli, Julinda, additional, Piñón, Pablo, additional, Martins, Dinis, additional, Avanzas, Pablo, additional, López-Mínguez, José R., additional, Martins, Cristina, additional, Santos, Ricardo, additional, Torres, Alfonso, additional, Lozano, Íñigo, additional, Moreno, Raúl, additional, Sabaté y, Manel, additional, and Hernández, Felipe, additional

Published
2021
Full Text
View/download PDF

109. Intervencionismo en el infarto de miocardio con elevación del segmento ST:: estado actual y perspectivas de futuro

Author

Ortega Paz, Luis, Brugaletta, Salvatore, Sabaté Tenas, Manel, Ortega Paz, Luis, Brugaletta, Salvatore, and Sabaté Tenas, Manel

Abstract

Ischemic heart disease is the most common cause of death worldwide. In patients with ST-segment elevation myocardial infarction (STEMI), optimizing primary percutaneous coronary intervention is crucial to improve prognosis. Over the years, many studies have been published on the value of second-generation stents, strategies to reduce myocardial damage, how to achieve complete revascularization and also on percutaneous mechanical circulatory support devices, which all are attractive therapeutic options to treat patients with STEMI complicated by cardiogenic shock. In this review we will be discussing how primary percutaneous coronary intervention can be optimized with respect to stent selection and revascularization strategy to reduce myocardial damage and improve clinical outcomes. In addition, we review published data on the use of mechanical circulatory support devices in patients with STEMI complicated by cardiogenic shock., La cardiopatía isquémica es la causa más común de mortalidad en todo el mundo. En pacientes con infarto agudo de miocardio con elevación del segmento ST (IAMCEST), la optimización de la intervención coronaria percutánea primaria es crucial para mejorar el pronóstico. Durante estos últimos años se han publicado muchos estudios sobre el valor de los stents de segunda generación, sobre estrategias para reducir el daño miocárdico, sobre cómo conseguir la revascularización completa y sobre dispositivos de apoyo circulatorio mecánico percutáneo que representan una opción terapéutica atractiva en pacientes con IAMCEST complicado con shock cardiogénico. En esta revisión se discute cómo se puede optimizar la intervención coronaria percutánea primaria con respecto a la selección de los stents y la estrategia de revascularización, con el fin de reducir el daño miocárdico y mejorar los resultados clínicos. Además, se revisan los datos publicados sobre el uso de dispositivos de apoyo circulatorio mecánico en pacientes con IAMCEST complicado por shock cardiogén

Published
2021

110. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction

Author

Brugaletta, Salvatore, Gomez-Lara, Josep, Ortega-Paz, Luis, Jimenez-Diaz, Victor, Jimenez, Marcelo, Jiménez-Quevedo, Pilar, Diletti, Roberto, Mainar, Vicente, Campo, Gianluca, Silvestro, Antonio, Maristany, Jaume, Flores, Xacobe, Oyarzabal, Loreto, De Miguel-Castro, Antonio, Iñiguez, Andrés, Serra, Antonio, Nombela-Franco, Luis, Ielasi, Alfonso, Tespili, Maurizio, Lenzen, Mattie, Gonzalo, Nieves, Bordes, Pascual, Tebaldi, Matteo, Biscaglia, Simone, Rodriguez-Arias, Juan Jose, Al-Shaibani, Soheil, Arevalos, Victor, Romaguera, Rafael, Gomez-Hospital, Joan Antoni, Serruys, Patrick W., Sabaté, Manel, Brugaletta, Salvatore, Gomez-Lara, Josep, Ortega-Paz, Luis, Jimenez-Diaz, Victor, Jimenez, Marcelo, Jiménez-Quevedo, Pilar, Diletti, Roberto, Mainar, Vicente, Campo, Gianluca, Silvestro, Antonio, Maristany, Jaume, Flores, Xacobe, Oyarzabal, Loreto, De Miguel-Castro, Antonio, Iñiguez, Andrés, Serra, Antonio, Nombela-Franco, Luis, Ielasi, Alfonso, Tespili, Maurizio, Lenzen, Mattie, Gonzalo, Nieves, Bordes, Pascual, Tebaldi, Matteo, Biscaglia, Simone, Rodriguez-Arias, Juan Jose, Al-Shaibani, Soheil, Arevalos, Victor, Romaguera, Rafael, Gomez-Hospital, Joan Antoni, Serruys, Patrick W., and Sabaté, Manel

Abstract

Background: Outcomes data for a durable-polymer everolimus-eluting stent (EES) at extended long-term follow-up in patients with ST-segment elevation myocardial infarction (STEMI) are unknown. Objectives: The aim of this study was to assess the 10-year outcomes of patients enrolled in the EXAMINATION (A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients With ST-Segment Elevation Myocardial Infarction) trial. Methods: The EXAMINATION-EXTEND (10-Years Follow-Up of the EXAMINATION Trial) study is an investigator-driven 10-year follow-up of the EXAMINATION trial, which randomly assigned 1,498 patients with STEMI in a 1:1 ratio to receive either EES (n = 751) or bare-metal stents (n = 747). The primary endpoint was a patient-oriented composite endpoint of all-cause death, any myocardial infarction, or any revascularization. Secondary endpoints included a device-oriented composite endpoint of cardiac death, target vessel myocardial infarction, or target lesion revascularization; the individual components of the combined endpoints; and stent thrombosis. Results: Complete 10-year clinical follow-up was obtained in 94.5% of the EES group and 95.9% of the bare-metal stent group. Rates of the patient-oriented composite endpoint and device-oriented composite endpoint were significantly reduced in the EES group (32.4% vs. 38.0% [hazard ratio: 0.81; 95% confidence interval: 0.68 to 0.96; p = 0.013] and 13.6% vs. 18.4% [hazard ratio: 0.72; 95% confidence interval: 0.55 to 0.93; p = 0.012], respectively), driven mainly by target lesion revascularization (5.7% vs. 8.8%; p = 0.018). The rate of definite stent thrombosis was similar in both groups (2.2% vs. 2.5%; p = 0.590). No differences were found between the groups in terms of target lesion revascularization (1.4% vs. 1.3%; p = 0.963) and definite or probable stent thrombosis (0.6% vs. 0.4%; p = 0.703) between 5 and 10 years. Conclusions: At 10-year follow-up, EES demonstrated confirmed superi

Published
2021

114. 10-Year Follow-Up of Patients With Everolimus-Eluting Versus Bare-Metal Stents After ST-Segment Elevation Myocardial Infarction

Author

Brugaletta, Salvatore, primary, Gomez-Lara, Josep, additional, Ortega-Paz, Luis, additional, Jimenez-Diaz, Victor, additional, Jimenez, Marcelo, additional, Jiménez-Quevedo, Pilar, additional, Diletti, Roberto, additional, Mainar, Vicente, additional, Campo, Gianluca, additional, Silvestro, Antonio, additional, Maristany, Jaume, additional, Flores, Xacobe, additional, Oyarzabal, Loreto, additional, De Miguel-Castro, Antonio, additional, Iñiguez, Andrés, additional, Serra, Antonio, additional, Nombela-Franco, Luis, additional, Ielasi, Alfonso, additional, Tespili, Maurizio, additional, Lenzen, Mattie, additional, Gonzalo, Nieves, additional, Bordes, Pascual, additional, Tebaldi, Matteo, additional, Biscaglia, Simone, additional, Rodriguez-Arias, Juan Jose, additional, Al-Shaibani, Soheil, additional, Arevalos, Victor, additional, Romaguera, Rafael, additional, Gomez-Hospital, Joan Antoni, additional, Serruys, Patrick W., additional, and Sabaté, Manel, additional

Published
2021
Full Text
View/download PDF

118. Bioresorbable scaffolds versus permanent sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction: vascular healing outcomes from the MAGSTEMI trial

Author

Gomez-Lara, Josep, primary, Ortega-Paz, Luis, additional, Brugaletta, Salvatore, additional, Cuesta, Javier, additional, Romaní, Sebastián, additional, Serra, Antonio, additional, Salinas, Pablo, additional, García del Blanco, Bruno, additional, Goicolea, Javier, additional, Hernandez-Antolín, Rosana, additional, Antuña, Paula, additional, Romaguera, Rafael, additional, Regueiro, Ander, additional, Rivero, Fernando, additional, Cequier, Àngel, additional, Alfonso, Fernando, additional, Gómez-Hospital, Joan Antoni, additional, and Sabaté, Manel, additional

Published
2020
Full Text
View/download PDF

119. TCT CONNECT-7 Everolimus-Eluting Stent Versus Bare-Metal Stent in ST-Segment Elevation Myocardial Infarction: 10-Year Follow-Up of the Multicenter Randomized Controlled Examination Trial

Author

Brugaletta, Salvatore, primary, Lara, Josep Gomez, additional, Ortega-Paz, Luis, additional, Jimenez Diaz, Victor Alfonso, additional, Jimenez, Marcelo, additional, Jimenez-Quevedo, Pilar, additional, Diletti, Roberto, additional, Tello, Vicente Mainar, additional, Campo, Gianluca, additional, Silvestro, Antonio, additional, Maristany, Jaume, additional, Flores-Rios, Xacobe, additional, Oyarzabal, Loreto, additional, Castro, Antonio Alejandro De Miguel, additional, Romo, Andres Iñiguez, additional, Serra, Antonio, additional, Franco, Luis Nombela, additional, Ielasi, Alfonso, additional, Tespili, Maurizio, additional, Lenzen, Mattie, additional, Gonzalo, Nieves, additional, Tebaldi, Matteo, additional, Biscaglia, Simone, additional, Rodriguez, Juan, additional, Al-Shaibani, Soheil, additional, Arevalos, Victor, additional, Romaguera, Rafael, additional, Gomez-Hospital, Joan Antoni, additional, Serruys, Patrick, additional, and Sabate, Manel, additional

Published
2020
Full Text
View/download PDF

122. Bioresorbable vascular scaffolds versus everolimus-eluting metallic stents in patients with ST-segment elevation myocardial infarction: 5-year results of the BVS-EXAMINATION study

Author

Brugaletta, Salvatore, primary, Gori, Tommaso, additional, Tousek, Petr, additional, Gomez-Lara, Josep, additional, Pinar, Eduardo, additional, Ortega-Paz, Luis, additional, Schulz, Eberhard, additional, Kocka, Viktor, additional, Münzel, Thomas, additional, Cequier, Àngel, additional, Buono, Andrea, additional, Serruys, Patrick W., additional, and Sabaté, Manel, additional

Published
2020
Full Text
View/download PDF

123. Recuperación a largo plazo de la función vascular en oclusiones coronarias crónicas totales tras su recanalización: Ensayo clínico aleatorizado de ticagrelor frente a clopidogrel

Author

Rodríguez Arias, Juan José, Gómez Lara, Josep, Caballero Callejas, Juan, Ortega Paz, Luis, Teruel, Luis, Romaguera Torres, Rafael, Correa Vilches, Concepción, Cequier Fillat, Angel, Sabaté Tenas, Manel, Brugaletta, Salvatore, Rodríguez Arias, Juan José, Gómez Lara, Josep, Caballero Callejas, Juan, Ortega Paz, Luis, Teruel, Luis, Romaguera Torres, Rafael, Correa Vilches, Concepción, Cequier Fillat, Angel, Sabaté Tenas, Manel, and Brugaletta, Salvatore

Abstract

Introducción y objetivos: La función vascular coronaria de una oclusión coronaria total crónica (CTO) inmediatamente después de su recanalización es pobre. Se desconoce si esta disfunción vascular se mantiene en el seguimiento a largo plazo y si existe una función protectora del tratamiento antiplaquetario doble (TAPD) de 1 año con ticagrelor frente a clopidogrel. Métodos: El estudio TIGER es un ensayo clínico prospectivo, doble aleatorizado, abierto, de dos grupos paralelos controlados, que ha asignado de forma aleatoria 1:1 los pacientes que recibieron una ICP de CTO exitosa a TAPD de 1 año con ticagrelor frente a clopidogrel. Adicionalmente, se asignó a los pacientes de forma aleatoria 1:1 a recibir un seguimiento angiográfico a 1 o 3 años. Inmediatamente después de la ICP y en el seguimiento angiográfico se evaluó el flujo coronario (CBF) bajo perfusión de dosis crecientes de adenosina y se realizó la comparación entre los 2 grupos. Resultados: Se incluyeron 50 pacientes asignados 1:1 a tratamiento con ticagrelor o clopidogrel (25 pacientes por grupo) y a seguimiento angiográfico a 1 o 3 años (25 pacientes por grupo). Finalmente recibieron un seguimiento angiográfico a 1 y 3 años 23 (92%) y 15 (60%) pacientes, respectivamente. Bajo infusión de dosis crecientes de adenosina se observó un área bajo la curva de CBF mayor con ticagrelor en comparación con el grupo de clopidogrel inmediatamente después de la ICP de CTO (32.122,91 ± 24.039,59 vs. 19.604,58 ± 11.204,20; p = 0,085). Esta tendencia persiste en el seguimiento (34.815,22 ± 24.206,06 vs. 22.712,47 ± 13.768,95; p = 0.071) sin ninguna interacción del tiempo de seguimiento y el fármaco antiagregante administrado. Dentro de cada grupo de tratamiento, mientras que en el grupo de ticagrelor el CBF mayor al principio se mantuvo durante el seguimiento, en el de clopidogrel hubo un aumento del CBF en el seguimiento comparado con el basal. Conclusiones: El ensayo TIGER mostró que el tratamiento de 1 año con ticagrelo

Published
2020

124. Ticagrelor versus clopidogrel for recovery of vascular function immediately after successful chronic coronary total occlusion recanalization: A randomized clinical trial

Author

Brugaletta, Salvatore, Gomez-Lara, Josep, Caballero, Juan, Ortega-Paz, Luis, Teruel, Luis, Fernandez, Miriam Jimenez, Romaguera, Rafael, Martinez, Vicente Alcalde, Ñato, Marcos, Navarro, Eduardo Molina, Gomez-Hospital, Joan-Antoni, Vilches, Concepcion Correa, Joyera, Maria, Cequier, Angel, Angiolillo, Dominick J, and Sabate, Manel

Published
2018
Full Text
View/download PDF

126. Does Large Vessel Size Justify Use of Bare-Metal Stents in Primary Percutaneous Coronary Intervention?

Author

Costa, Francesco, Brugaletta, Salvatore, Pernigotti, Alberto, Flores-Ulmanzor, Eduardo, Ortega-Paz, Luis, Cequier, Angel, Iniguez, Andres, Serra, Antoni, Jiménez-Quevedo, Pilar, Mainar, Vicente, Campo, Gianluca, Tespili, Maurizio, Den Heijer, Peter, Bethencourt, Armando, Vazquez, Nicolás, Van Es, Gerrit Anne, Backx, Bianca, Valgimigli, Marco, Serruys, Patrick, and Sabaté, Manel

Subjects
610 Medicine & health
Abstract

BACKGROUND Drug-eluting stents (DES) showed improved efficacy and safety compared with bare-metal stents (BMS), and international guidelines recommend their use as first line treatment. Yet, BMS are still widely used in practice, especially in large coronary vessels. We aimed to compare efficacy and safety of second-generation DES over BMS in large coronary culprit ST-segment elevated myocardial infarction lesions. METHODS We evaluated impact of large coronary stents (maximum size ≥3.50 mm) or smaller stents (

Published
2019
Full Text
View/download PDF

127. Management of Heart Failure with Reduced Ejection Fraction after ESC 2016 Heart Failure Guidelines: The Linx Registry

Author

Frutos, Fernando, primary, Mirabet, Sonia, additional, Ortega‐Paz, Luis, additional, Buera, Irene, additional, Darnés, Sara, additional, Farré, Nuria, additional, Perez, Bernardo, additional, Adeliño, Raquel, additional, Bascompte, Ramón, additional, Pérez‐Rodón, Jordi, additional, Aparicio, Xavier, additional, Sutil‐Vega, Mario, additional, Soto, Adriana, additional, Faraudo, Mercedes, additional, Cainzos‐Achirica, Miguel, additional, and Manito, Nicolás, additional

Published
2020
Full Text
View/download PDF

132. Impact of Absorb bioresorbable scaffold implantation technique on post-procedural quantitative coronary angiographic endpoints in ST-elevation myocardial infarction: a sub-analysis of the BVS STEMI STRATEGY-IT study

Author

Hioki, Hirofumi, primary, Brugaletta, Salvatore, additional, Ishida, Kohki, additional, Campo, Gianluca, additional, Biscaglia, Simone, additional, Ortega-Paz, Luis, additional, Cortese, Bernardo, additional, Varricchio, Attilio, additional, Latib, Azeem, additional, Sabaté, Manel, additional, Tespili, Maurizio, additional, and Ielasi, Alfonso, additional

Published
2019
Full Text
View/download PDF

133. Long-term effects of coronavirus disease 2019 on the cardiovascular system, CV COVID registry: A structured summary of a study protocol.

Author

Arévalos, Victor, Ortega-Paz, Luis, Fernandez-Rodríguez, Diego, Alfonso Jiménez-Díaz, Víctor, Rius, Jordi Bañeras, Campo, Gianluca, Rodríguez-Santamarta, Miguel, de Prado, Armando Pérez, Gómez-Menchero, Antonio, Díaz Fernández, José Francisco, Scardino, Claudia, Gonzalo, Nieves, Pernigotti, Alberto, Alfonso, Fernando, Jesús Amat-Santos, Ignacio, Silvestro, Antonio, Ielasi, Alfonso, María de la Torre, José, Bastidas, Gabriela, and Gómez-Lara, Josep

Subjects
*COVID-19, *CARDIOVASCULAR diseases, *RESEARCH protocols, *CARDIOVASCULAR system, *MYOCARDIAL infarction, *HEART failure
Abstract

Background: Patients presenting with the coronavirus-2019 disease (COVID-19) may have a high risk of cardiovascular adverse events, including death from cardiovascular causes. The long-term cardiovascular outcomes of these patients are entirely unknown. We aim to perform a registry of patients who have undergone a diagnostic nasopharyngeal swab for SARS-CoV-2 and to determine their long-term cardiovascular outcomes. Study and design: This is a multicenter, observational, retrospective registry to be conducted at 17 centers in Spain and Italy (ClinicalTrials.gov number: NCT04359927). Consecutive patients older than 18 years, who underwent a real-time reverse transcriptase-polymerase chain reaction (RT-PCR) for SARS-CoV2 in the participating institutions, will be included since March 2020, to August 2020. Patients will be classified into two groups, according to the results of the RT-PCR: COVID-19 positive or negative. The primary outcome will be cardiovascular mortality at 1 year. The secondary outcomes will be acute myocardial infarction, stroke, heart failure hospitalization, pulmonary embolism, and serious cardiac arrhythmias, at 1 year. Outcomes will be compared between the two groups. Events will be adjudicated by an independent clinical event committee. Conclusion: The results of this registry will contribute to a better understanding of the long-term cardiovascular implications of the COVID19. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

134. Efecto de la técnica de implantación en los resultados en pacientes tratados con armazón bioabsorbible en diferentes escenarios clínicos

Author

Ortega Paz, Luis, Brugaletta, Salvatore, Latib, Azeem, Benedicto Buendía, Amparo, Naber, Christoph K., Salinas Sanguino, Pablo, Sanchís García, J.M., Piñón Esteban, Pablo, Íñiguez Romo, Andrés, Torres, Alfonso, Moreno Gómez, Raúl, Gori, Tommaso, Trillo Nouche, Ramiro, Caramanno, Giuseppe, Martins, Dinis, Martins, Cristina, Santos, Ricardo, Pérez de Prado, Armando, Mehilli, Julinda, Capodanno, Davide, Nef, Holger M., Di Mario, Carlo, López Mínguez, José Ramón, Lozano, Iñigo, Hernández Hernández, Felipe, Sabaté Tenas, Manel, Gómez-Hospital, Joan A., Urbano Carrillo, Cristóbal A., Avanzas Fernández, Pablo, Ortega Paz, Luis, Brugaletta, Salvatore, Latib, Azeem, Benedicto Buendía, Amparo, Naber, Christoph K., Salinas Sanguino, Pablo, Sanchís García, J.M., Piñón Esteban, Pablo, Íñiguez Romo, Andrés, Torres, Alfonso, Moreno Gómez, Raúl, Gori, Tommaso, Trillo Nouche, Ramiro, Caramanno, Giuseppe, Martins, Dinis, Martins, Cristina, Santos, Ricardo, Pérez de Prado, Armando, Mehilli, Julinda, Capodanno, Davide, Nef, Holger M., Di Mario, Carlo, López Mínguez, José Ramón, Lozano, Iñigo, Hernández Hernández, Felipe, Sabaté Tenas, Manel, Gómez-Hospital, Joan A., Urbano Carrillo, Cristóbal A., and Avanzas Fernández, Pablo

Abstract

Introduction and objectives: The PSP (pre-dilation, sizing and post-dilation) score, derived from the GHOST-EU registry, has evaluated the relationship between the implantation technique of bioresorbable scaffolds and the clinical outcomes. The objective was to perform an external validation of the PSP technique and to determine its effect on adverse cardiac events in various clinical and anatomical scenarios. Methods: Data from the REPARA registry (2230 patients) were used for external validation, whereas a common database combining REPARA and GHOST-EU (3250 patients) data was used to evaluate the effect of PSP technique in various clinical and anatomical scenarios. PSP-1 and PSP-3 were used to score the appropriateness of pre-dilation, scaffold sizing, and post-dilation. The primary endpoint was 1-year device-oriented composite endpoint of cardiac death, target-vessel myocardial infarction, and target-lesion revascularization. The definite/probable scaffold thrombosis according to the Academic Research Consortium criteria was also evaluated. Results: A total of 303 (18.2%) patients were treated with an optimal PSP-1, and 182 (8.2%) with an optimal PSP-3. The external validation showed that PSP has a very high negative predictive value for device-oriented composite endpoint and scaffold thrombosis (91.8% and 89.1% for PSP-1; 98.4% and 97.3% for PSP-3, respectively). Patients with an optimal PSP-3 had a numerically lower rate of device-oriented composite endpoint and scaffold thrombosis compared to those without it (0.5% vs 2.9%; P = .085 and 0.5% vs 1.8%; P = .248, respectively). In the merged database, PSP benefits were seen on many scenarios, except in the ST-segment elevation myocardial infarction where a trend towards no benefit of an optimal PSP technique was present (Pinteraction = .100). Conclusions: In the REPARA registry, at 1-year follow-up, an optimal PSP technique was not associated with a lower rate of device-oriented composite endpoint. Further resear, Introducción y objetivos: La escala de puntuación PSP (pre-dilation, sizing and post-dilation), derivada del registro GHOST-EU, evalúa la relación entre la técnica de implante de los armazones bioabsorbibles y los resultados clínicos. El objetivo fue realizar una validación externa de la escala PSP y determinar su efecto en eventos adversos cardiacos en diversos escenarios clínicos y anatómicos. Métodos: Para la validación externa se emplearon los datos del registro REPARA (2.230 pacientes), mientras que se utilizó una base de datos común que combina datos de REPARA y GHOST-EU (3.250 pacientes) para evaluar el efecto de la técnica PSP en varios escenarios clínicos y anatómicos. Se usó PSP-1 y PSP-3 para calificar la calidad de la predilatación, el dimensionamiento de los armazones y la posdilatación. El objetivo primario fue la variable compuesta orientada al dispositivo (muerte cardiaca, infarto de miocardio del vaso diana y revascularización de la lesión diana) a 1 año. También se evaluó la trombosis definitiva o probable del armazón según los criterios del Academic Research Consortium. Resultados: Se trató a 303 (18,2%) pacientes con una PSP-1 óptima y a 182 (8,2%) con una PSP-3 óptima. La validación externa mostró que la escala PSP tiene un valor predictivo negativo muy alto para el objetivo primario compuesto orientado al dispositivo y la trombosis del armazón (91,8 y 89,1% para PSP-1; 98,4 y 97,3% para PSP-3, respectivamente). En pacientes con PSP-3 óptimo, el objetivo primario compuesto orientado al dispositivo y la trombosis del armazón fueron numéricamente inferiores en comparación con los pacientes sin PSP-3 óptimo (0,5 frente a 2,9%; p = 0,085; y 0,5 frente a 1,8%; p = 0,248, respectivamente). En la base de datos combinada, los beneficios de la escala PSP se observaron en diversos escenarios, excepto en el de infarto de miocardio con elevación del segmento ST, en el que se observó una tendencia hacia laausencia de beneficios de una técnica de PSP óptima (

Published
2019

135. Función endotelial y microvascular distal a stentsfarmacoactivos sin polímero y captadores de células endoteliales. Estudio aleatorizado FUNCOMBO

Author

Gómez-Lara, Josep, Oyarzabal, Loreto, Brugaletta, Salvatore, Salvatella, Neus, Romaguera, Rafael, Roura, Gerard, Fuentes, Lara, Pérez Fuentes, Pedro, Ortega-Paz, Luis, Ferreiro, José L., Teruel, Luis, Gracida, Montserrat, Vaquerizo, Beatriz, Sabaté, Manel, Comín-Colet, Josep, and Gómez-Hospital, Joan-Antoni

Abstract

Aún no se conoce la función endotelial de los nuevos stentsfarmacoactivos diseñados para promover el recubrimiento y la reendotelización. El objetivo principal es comparar la función endotelial de la arteria responsable del infarto (ARI) tratada con stentsbioactivos liberadores de sirolimus captadores de células progenitoras endoteliales circulantes (SES; COMBO) frente a la tratada con stentssin polímero liberadores de biolimus (BES; Biofreedom), así como comparar la función microvascular de la ARI y el grado de cicatrización de ambos dispositivos a los 6 meses.

Published
2021
Full Text
View/download PDF

138. Reply

Author

Ortega-Paz, Luis, primary and Valgimigli, Marco, additional

Published
2018
Full Text
View/download PDF

139. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers

Author

Ariotti, Sara, primary, Ortega-Paz, Luis, additional, van Leeuwen, Maarten, additional, Brugaletta, Salvatore, additional, Leonardi, Sergio, additional, Akkerhuis, K. Martijn, additional, Rimoldi, Stefano F., additional, Janssens, Gladys, additional, Gianni, Umberto, additional, van den Berge, Jan C., additional, Karagiannis, Alexios, additional, Windecker, Stephan, additional, Valgimigli, Marco, additional, Frigoli, Enrico, additional, Monti, Monia, additional, Ciociano, Nestor, additional, Heg, Dik, additional, Rizzotti, Diego, additional, Mandurino Mirizzi, Alessandro, additional, Van Royen, Niels, additional, Räber, Lorenz, additional, Ariotti, Sara, additional, Rexhaj, Emrush, additional, and Sabaté, Manel, additional

Published
2018
Full Text
View/download PDF

140. Association between coronary atherosclerosis progression and in-stent neoatherosclerosis in patients with ST-elevation myocardial infarction at five-year follow-up

Author

Paoletti, Giulia, primary, Gomez-Lara, Josep, additional, Brugaletta, Salvatore, additional, Ñato, Marcos, additional, Romaguera, Rafael, additional, Roura, Gerard, additional, Ferreiro, José-Luis, additional, Teruel, Luis, additional, Gracida, Montserrat, additional, Ortega-Paz, Luis, additional, Gomez-Hospital, Joan-Antoni, additional, Sabaté, Manel, additional, and Cequier, Àngel, additional

Published
2018
Full Text
View/download PDF

141. Correlates of non-target vessel-related adverse events in patients with ST-segment elevation myocardial infarction: insights from five-year follow-up of the EXAMINATION trial

Author

Spitaleri, Giosafat, primary, Moscarella, Elisabetta, additional, Brugaletta, Salvatore, additional, Pernigotti, Alberto, additional, Ortega-Paz, Luis, additional, Gomez-Lara, Josep, additional, Cequier, Angel, additional, Iñiguez, Andres, additional, Serra, Antonio, additional, Jiménez-Quevedo, Pilar, additional, Mainar, Vicente, additional, Campo, Gianluca, additional, Tespili, Maurizio, additional, den Heijer, Peter, additional, Bethencourt, Armando, additional, Vazquez, Nicolás, additional, Valgimigli, Marco, additional, Serruys, Patrick W., additional, and Sabaté, Manel, additional

Published
2018
Full Text
View/download PDF

142. Effects of Ticagrelor, Prasugrel, or Clopidogrel at Steady State on Endothelial Function

Author

Ariotti, Sara, primary, van Leeuwen, Maarten, additional, Brugaletta, Salvatore, additional, Leonardi, Sergio, additional, Akkerhuis, K. Martijn, additional, Rimoldi, Stefano F., additional, Janssens, Gladys N., additional, Ortega-Paz, Luis, additional, Gianni, Umberto, additional, van den Berge, Jan C., additional, Karagiannis, Alexios, additional, Windecker, Stephan, additional, and Valgimigli, Marco, additional

Published
2018
Full Text
View/download PDF

148. TCT-168 TIcaGrEloR and ABSORB Bioresorbable Vascular Scaffold implantation for recovery of vascular function after successful Chronic Total Occlusion recanalization

Author

Brugaletta, Salvatore, primary, Lara, Josep Gomez, additional, Caballero-Borrego, Juan, additional, Ortega-Paz, Luis, additional, Gila, Luis Teruel, additional, Jimenez, Miriam, additional, Romaguera, Rafael, additional, Martinez, Vicente Alcalde, additional, Ñato, Marcos, additional, Molina, Eduardo, additional, Gomez-Hospital, Joan Antoni, additional, Vilchez, Concepcion Correa, additional, Cequier, Angel, additional, and Sabate, Manel, additional

Published
2017
Full Text
View/download PDF

150. Impact of stent overlapping on long-term clinical outcomes in patients with ST-segment elevation myocardial infarction: insights from the five-year follow-up of the EXAMINATION trial

Author

Ortega-Paz, Luis, primary, Brugaletta, Salvatore, additional, Giacchi, Giuseppe, additional, Ishida, Kohki, additional, Cequier, Angel, additional, Iñiguez, Andrés, additional, Serra, Antonio, additional, Jiménez-Quevedo, Pilar, additional, Mainar, Vicente, additional, Campo, Gianluca, additional, Tespili, Maurizio, additional, den Heijer, Peter, additional, Valgimigli, Marco, additional, Serruys, Patrick, additional, and Sabaté, Manel, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results